Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of Ramadan in Muslim Patients with Type 2 Diabetes

Journal Title: Oman Medical Journal - Year 2018, Vol 33, Issue 2

Abstract

Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) are a new class of antidiabetic drugs that might increase the risk of dehydration and hypoglycemia, particularly during the month of Ramadan in which Muslims abstain from eating and drinking for 14–16 hours daily. We aimed to provide real-life evidence about the safety of SGLT2-I during Ramadan. Methods: All patients over the age of 18 years on SGLT2-I before Ramadan 2016 who would be fasting during Ramadan were included. Demographic data, detailed medical history including comorbidities and medication profile, and laboratory results were collected before and after Ramadan. We also conducted a phone interview to evaluate the frequency and severity of hypoglycemia and dehydration. Results: Of the total of 417 patients, 113 (27.0%) experienced hypoglycemic events, and 93 of these (82.3%) checked their blood glucose using a glucometer. Confirmed hypoglycemia (< 70 mg/dL) was observed in 78 (83.8%). The hypoglycemic events were significantly more frequent in the SGLT2-I plus insulin-treated group than in those treated with SGLT2-I plus oral hypoglycemic agents group (p < 0.001). Confirmed hypoglycemic events were more frequent in those using SGLT2-I plus intensive insulin compared to those using SGLT2-I plus basal insulin (p = 0.020). Symptoms of dehydration were seen in 9.3% (n = 39) of the total population. We observed statistically significant reductions in glycated hemoglobin and weight by the end of Ramadan (p < 0.001). There were no significant changes in lipid profile and creatinine levels by the end of the study. Conclusions: The use of insulin in combination with SGLT2-I increases the risk of hypoglycemia during Ramadan. Hypoglycemic events were mild and did not require hospital admission. However, careful monitoring during prolonged fasting is warranted. No significant harmful effects on renal function result from treatment with SGLT2-I during Ramadan.

Authors and Affiliations

Alaaeldin Bashier, Azza Abdulaziz Khalifa, Elamin Ibrahim Abdelgadir, Maryam Ahmad Al Saeed, Amina Adil Al Qaysi, Murad Burhan Ali Bayati, Budoor Alemadi, Fawzi Bachet, Fatheya Alawadi, Mohammed Hassanein

Keywords

Related Articles

Pneumorrhachis with Spontaneous Pneumomediastinum: Should It Raise Special Concerns?

Spontaneous pneumomediastinum (SPM) is a rare and benign condition predominantly seen in young males. Patients present with non-specific pleuritic chest pain, cough, and dyspnea. Hence, it is difficult to diagnose in the...

Correlation between Serum Level of Antiepileptic Drugs and their Side Effects

Objectives: The aim of the study is to investigate the relation between serum levels of anticonvulsants and their side effects. Methods: This is a prospective cross sectional hospital based study conducted at Al Shaa...

Inflammatory Pseudotumor of the Spleen Masquerading as Splenic Malignancy

Inflammatory pseudotumors (IPTs) of the spleen are extremely rare, benign tumors of unknown etiology, and are most frequently detected incidentally. We report a case of IPT of the spleen in a 19-year-old male, who presen...

Vaginal Reconstruction for Vaginal Obliteration Secondary to Stevens Johnson Syndrome: A Case Report and Review of Literature

Stevens-Johnson syndrome (SJS) is a rare and acute life-threatening condition which is almost always precipitated by drugs. Genital mucositis in female patients may also be an important cause of long-term morbidity secon...

The Tip of the Iceberg in Maternally Inherited Diabetes and Deafness

Maternally inherited diabetes and deafness (MIDD) is not only a disorder of the pancreas and ears but a multisystem mitochondrial disorder syndrome. Hypogonadism, however, has not been reported as a phenotypic feature of...

Download PDF file
  • EP ID EP278023
  • DOI 10.5001/omj.2018.21
  • Views 78
  • Downloads 0

How To Cite

Alaaeldin Bashier, Azza Abdulaziz Khalifa, Elamin Ibrahim Abdelgadir, Maryam Ahmad Al Saeed, Amina Adil Al Qaysi, Murad Burhan Ali Bayati, Budoor Alemadi, Fawzi Bachet, Fatheya Alawadi, Mohammed Hassanein (2018). Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of Ramadan in Muslim Patients with Type 2 Diabetes. Oman Medical Journal, 33(2), 104-110. https://www.europub.co.uk/articles/-A-278023